The Future of anti-EGFR Therapy? – Part 1

Last month in my blogs I discussed a few completely experimental CRC drug strategies in early phase clinical trials. Drug discovery isn’t all about venturing into the complete unknown however. Identifying ways to significantly improve current therapeutic strategies that have…  Read More

Colorectal Cancer News in Brief: November 1

Briefly: Pancreatic cancer occurs in about on in five Lynch syndrome families, increasing risk for the cancer substantially. Colorectal cancer patients whose tumors don’t have EGFR on immunohistochemical testing can still benefit from Erbitux treatment. Patients learn more and like…  Read More